Bertrand Degos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/308111/publications.pdf

Version: 2024-02-01

77 papers 2,656 citations

186265
28
h-index

206112 48 g-index

88 all docs 88 docs citations

88 times ranked 4061 citing authors

#	Article	lF	Citations
1	Impaired social cognition and fine dexterity in patients with Cowden syndrome associated with germline <i>PTEN </i> i>variants. Journal of Medical Genetics, 2023, 60, 91-98.	3.2	1
2	Neurological consequences of recreational nitrous oxide abuse during SARS-CoV-2 pandemic. Journal of Neurology, 2022, 269, 1921-1926.	3.6	12
3	Somatotopy of cervical dystonia in motor-cerebellar networks: Evidence from resting state fMRI. Parkinsonism and Related Disorders, 2022, 94, 30-36.	2.2	7
4	The "Neurospeed―game: a fun tool to learn the neurological semiology. BMC Medical Education, 2022, 22, 224.	2.4	4
5	Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. Movement Disorders, 2022, 37, 1245-1255.	3.9	8
6	FXTAS patient presenting as Huntington-like generalized chorea. Revue Neurologique, 2021, 177, 445-446.	1.5	1
7	Automated Categorization of Parkinsonian Syndromes Using <scp>Magnetic Resonance Imaging </scp> in a Clinical Setting. Movement Disorders, 2021, 36, 460-470.	3.9	27
8	The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain Communications, 2021, 3, fcab135.	3.3	16
9	Persistent bilateral Tapia syndrome following critical COVID-19. Clinical Neurophysiology, 2021, 132, 505-506.	1.5	7
10	Transâ€Spinal Direct Current Stimulation for Managing Primary Orthostatic Tremor. Movement Disorders, 2021, 36, 1835-1842.	3.9	10
11	Thrombocytopenia and agranulocytosis in a FXTAS choreic patient treated with tetrabenazine. Neurological Sciences, 2021, 42, 3475-3477.	1.9	2
12	Fluoxetine-induced chorea. Revue Neurologique, 2021, 177, 1010-1011.	1.5	3
13	Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study. Npj Parkinson's Disease, 2021, 7, 50.	5. 3	29
14	Extended amantadine-induced livedo reticularis. Revue Neurologique, 2021, 177, 1301-1303.	1.5	0
15	A single-center series of 482 patients with functional motor disorders. Journal of Psychosomatic Research, 2021, 148, 110565.	2.6	2
16	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	2.6	1
17	Visual Sensory Processing is Altered in Myoclonus Dystonia. Movement Disorders, 2020, 35, 151-160.	3.9	6
18	Functional Motor Symptoms in Parkinson's Disease and Functional Parkinsonism: A Systematic Review. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 4-13.	1.8	37

#	Article	IF	Citations
19	Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy. Movement Disorders, 2020, 35, 161-170.	3.9	31
20	The Role of Magnetic Resonance Imaging for the Diagnosis of Atypical Parkinsonism. Frontiers in Neurology, 2020, 11, 665.	2.4	22
21	Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort. Frontiers in Neurology, 2020, 11, 682.	2.4	28
22	COVIDâ€19â€related encephalopathy: a case series with brain FDGâ€positronâ€emission tomography/computed tomography findings. European Journal of Neurology, 2020, 27, 2651-2657.	3.3	127
23	Tactile Temporal Discrimination Is Impaired in Myoclonusâ€Dystonia. Movement Disorders, 2020, 35, 2356-2357.	3.9	1
24	Dissociation in reactive and proactive inhibitory control in Myoclonus dystonia. Scientific Reports, 2020, 10, 13933.	3.3	2
25	Prospective study on a fast-track training in psychiatry for medical students: the psychiatric hat game. BMC Medical Education, 2020, 20, 373.	2.4	3
26	Post SARS-CoV-2 Guillain-Barré syndrome. Clinical Neurophysiology, 2020, 131, 1652-1654.	1.5	71
27	Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms. Nature Communications, 2020, 11, 2388.	12.8	37
28	Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism and Related Disorders, 2020, 75, 30-33.	2.2	10
29	Isolated post SARS-CoV-2 diplopia. Journal of Neurology, 2020, 267, 3128-3129.	3.6	23
30	Are PSP patients included in clinical trials representative of the general PSP population?. Parkinsonism and Related Disorders, 2019, 66, 202-206.	2.2	3
31	Invalidation of Parkinson's disease diagnosis after years of follow-up based on clinical, radiological and neurophysiological examination. Journal of the Neurological Sciences, 2019, 406, 116454.	0.6	2
32	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. Parkinsonism and Related Disorders, 2019, 64, 226-234.	2.2	4
33	Functional classification of <i>ATM</i> variants in ataxiaâ€telangiectasia patients. Human Mutation, 2019, 40, 1713-1730.	2.5	27
34	Quality of life in functional movement disorders is as altered as in organic movement disorders. Journal of Psychosomatic Research, 2019, 116, 10-16.	2.6	24
35	The supplementary motor area modulates interhemispheric interactions during movement preparation. Human Brain Mapping, 2019, 40, 2125-2142.	3.6	44
36	Incobotulinum toxin A in Parkinson's disease with foot dystonia: AÂdouble blind randomized trial. Parkinsonism and Related Disorders, 2018, 46, 9-15.	2.2	28

#	Article	IF	CITATIONS
37	Dopamine–endocannabinoid interactions mediate spike-timing-dependent potentiation in the striatum. Nature Communications, 2018, 9, 4118.	12.8	29
38	Short-term temporal memory in idiopathic and Parkin-associated Parkinson's disease. Scientific Reports, 2018, 8, 7637.	3.3	10
39	Adult-onset Generalized Dystonia as the Main Manifestation of MEGDEL Syndrome. Tremor and Other Hyperkinetic Movements, 2018, 8, 554.	2.0	5
40	Axonal Neuropathies due to Mutations in Small Heat Shock Proteins: Clinical, Genetic, and Functional Insights into Novel Mutations. Human Mutation, 2017, 38, 556-568.	2.5	54
41	"De-novo―consultation: Evaluation of an outpatient's clinic dedicated to early diagnosis of parkinsonian syndromes. Revue Neurologique, 2017, 173, 55-61.	1.5	3
42	Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders. Movement Disorders, 2017, 32, 693-704.	3.9	54
43	A Selective Role for Dopamine in Learning to Maximize Reward But Not to Minimize Effort: Evidence from Patients with Parkinson's Disease. Journal of Neuroscience, 2017, 37, 6087-6097.	3.6	48
44	Outcome of gastrostomy in parkinsonism: A retrospective study. Parkinsonism and Related Disorders, 2017, 43, 110-113.	2.2	12
45	Impact of Transcranial Magnetic Stimulation on Functional Movement Disorders: Cortical Modulation or a Behavioral Effect?. Frontiers in Neurology, 2017, 8, 338.	2.4	49
46	The long-term outcome of orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309942.	1.9	100
47	Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial. PLoS ONE, 2016, 11, e0158235.	2.5	39
48	Explicit Agency in Patients with Cervical Dystonia: Altered Recognition of Temporal Discrepancies between Motor Actions and Their Feedback. PLoS ONE, 2016, 11, e0162191.	2.5	14
49	Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study. Journal of Neurology, 2016, 263, 1111-1119.	3.6	57
50	Orthostatic tremor: a cerebellar pathology?. Brain, 2016, 139, 2182-2197.	7.6	49
51	Computational Dissection of Dopamine Motor and Motivational Functions in Humans. Journal of Neuroscience, 2016, 36, 6623-6633.	3.6	109
52	PINK1 and FLNA mutations association: A role for atypical parkinsonism?. Parkinsonism and Related Disorders, 2016, 26, 78-80.	2.2	0
53	Motor and non-motor symptoms in functional parkinsonism responsive to transcranial magnetic stimulation: a case report. Journal of Neurology, 2016, 263, 816-817.	3.6	4
54	Cat Bite: An Unusual Cause of Foot Drop. American Journal of Medicine, 2016, 129, e9-e10.	1.5	1

#	Article	IF	CITATIONS
55	Apomorphine Therapy: The Hazard of Left Over Needles. Movement Disorders Clinical Practice, 2015, 2, 199-200.	1.5	1
56	Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease. PLoS ONE, 2015, 10, e0142838.	2.5	23
57	<i>ADCY5</i> -related dyskinesia. Neurology, 2015, 85, 2026-2035.	1.1	163
58	From splitting GLUT1 deficiency syndromes to overlapping phenotypes. European Journal of Medical Genetics, 2015, 58, 443-454.	1.3	52
59	Intrinsic signature of essential tremor in the cerebello-frontal network. Brain, 2015, 138, 2920-2933.	7.6	87
60	A diagnostic flow chart for <i>POLG-</i> related diseases based on signs sensitivity and specificity. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 646-654.	1.9	30
61	POLG mutations associated with remitting/relapsing neurological events. Journal of Clinical Neuroscience, 2014, 21, 186-188.	1.5	6
62	From anti-GAD to ataxia with ocular motor apraxia type 2: through the looking glass. Journal of Neurology, 2013, 260, 1158-1159.	3.6	1
63	Blepharospasm as a new feature of cerebrotendinous xanthomatosis. Parkinsonism and Related Disorders, 2013, 19, 764-765.	2.2	5
64	Defective cerebellar control of cortical plasticity in writer's cramp. Brain, 2013, 136, 2050-2062.	7.6	94
65	Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1043-1046.	1.9	61
66	Subthalamic Nucleus High-Frequency Stimulation Restores Altered Electrophysiological Properties of Cortical Neurons in Parkinsonian Rat. PLoS ONE, 2013, 8, e83608.	2.5	29
67	Myoclonus and dystonia in cerebrotendinous xanthomatosis. Movement Disorders, 2012, 27, 1805-1810.	3.9	33
68	Portosystemic shunts: An underdiagnosed but treatable cause of neurological and psychiatric disorders. Journal of the Neurological Sciences, 2012, 321, 58-64.	0.6	15
69	Subthalamic nucleus highâ€frequency stimulation generates a concomitant synaptic excitation–inhibition in substantia nigra pars reticulata. Journal of Physiology, 2011, 589, 4189-4207.	2.9	34
70	Deep brain stimulation mechanisms: beyond the concept of local functional inhibition. European Journal of Neuroscience, 2010, 32, 1080-1091.	2.6	166
71	Biotin-Responsive Basal Ganglia Disease in Ethnic Europeans With Novel SLC19A3 Mutations. Archives of Neurology, 2010, 67, 126-30.	4.5	93
72	Striatal Medium-Sized Spiny Neurons: Identification by Nuclear Staining and Study of Neuronal Subpopulations in BAC Transgenic Mice. PLoS ONE, 2009, 4, e4770.	2.5	214

#	Article	IF	CITATIONS
73	Assessment of bursting activity and interspike intervals variability: A case study for methodological comparison. Journal of Neuroscience Methods, 2009, 179, 142-149.	2.5	21
74	Evidence for a direct subthalamoâ€cortical loop circuit in the rat. European Journal of Neuroscience, 2008, 27, 2599-2610.	2.6	92
75	NDRG1-linked Charcot-Marie-Tooth disease (CMT4D) with central nervous system involvement. Neuromuscular Disorders, 2007, 17, 163-168.	0.6	35
76	Neuroleptic-Induced Catalepsy: Electrophysiological Mechanisms of Functional Recovery Induced by High-Frequency Stimulation of the Subthalamic Nucleus. Journal of Neuroscience, 2005, 25, 7687-7696.	3.6	99
77	A carpenter with dementia. Lancet, The, 2003, 362, 1647.	13.7	0